Opioid mortality rates continue to increase throughout the United States1; however, growth in buprenorphine hydrochloride treatment for opioid use disorder (OUD) might be limited to communities with higher income and low percentages of racial/ethnic minorities.2 Buprenorphine, a partial opioid agonist, is 1 of 3 evidence-based medications for treating OUD and can legally be prescribed in office-based settings.
Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race/Ethnicity and Payment. JAMA Psychiatry. Published online May 08, 201976(9):979–981. doi:10.1001/jamapsychiatry.2019.0876
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: